According to Mengke Pharmaceutical's announcement, the restricted shares listed and circulated were some of the restricted shares prior to the initial public offering, totaling 795.23,500 shares, accounting for 12.13% of the company's total share capital, involving 3 shareholders, including GeniePharma, Mengke Hong Kong, and Xinyi Youmai. This portion of the restricted shares will be listed and circulated on January 5, 2026. Since the company's listing, the total share capital has increased from 655,210,084 shares to 655,605,491 shares due to the implementation of the 2023 restricted stock incentive plan. The sponsor agency has no objection to the lifting of the ban on listing and circulation of restricted shares.

According to Mengke Pharmaceutical's announcement, the restricted shares listed and circulated were some of the restricted shares prior to the initial public offering, totaling 795.23,500 shares, accounting for 12.13% of the company's total share capital, involving 3 shareholders, including GeniePharma, Mengke Hong Kong, and Xinyi Youmai. This portion of the restricted shares will be listed and circulated on January 5, 2026. Since the company's listing, the total share capital has increased from 655,210,084 shares to 655,605,491 shares due to the implementation of the 2023 restricted stock incentive plan. The sponsor agency has no objection to the lifting of the ban on listing and circulation of restricted shares.